1340-1341 / 2063
• FLAME-trial
Randomized phase III trial
• Standard arm: 77 Gy/2.2 Gy (35 fr) to the prostate
• Experimental arm: additional integrated boost to macroscopically
visible tumor, delineated based on 2 different imaging techniques, to
a maximal total dose of 95 Gy (35 fr of 2.7 Gy)
– Primary endpoint
• To decrease the 5-year biochemical relapse rate with at least 10%